Dyne Therapeutics Inc (DYN)

$10.05 +0.20 (2.03%)
Market Cap 1.41B
Revenue (ttm) 0.00
Net Income (ttm) -317.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,751,600
Avg Vol 2,791,368
Day's Range N/A - N/A
Shares Out 142.26M
Stochastic %K 72%
Beta 1.08
Analysts Strong Sell
Price Target $38.20

Company Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 786 8230
Fax: 781 786 8866
Address:
1560 Trapelo Road, Waltham, United States
Jewstock
Jewstock Aug. 1 at 4:34 PM
$DYN what’s happening here 😳
0 · Reply
JarvisFlow
JarvisFlow Jul. 31 at 3:51 PM
Stifel has adjusted their stance on Dyne Therapeutics ( $DYN ), setting the rating to Buy with a target price of 66 → 36.
0 · Reply
Sam201
Sam201 Jul. 30 at 5:31 PM
$DYN load whenever it dips!
0 · Reply
Jewstock
Jewstock Jul. 30 at 2:15 PM
$DYN let’s go!
0 · Reply
anachartanalyst
anachartanalyst Jul. 29 at 11:01 AM
$DYN https://anachart.com/wp-content/uploads/ana_temp/1753786884_soc-img.jpg
0 · Reply
DonCorleone77
DonCorleone77 Jul. 28 at 8:14 PM
$DYN Dyne Therapeutics reports Q2 EPS (97c), consensus (93c) -- Dyne Therapeutics expects cash to fund operations into Q3 of 2027
0 · Reply
Sam201
Sam201 Jul. 28 at 3:39 PM
$DYN got myself another 300 shares!
0 · Reply
StocksNCash
StocksNCash Jul. 25 at 7:13 PM
$DYN looking 💪
0 · Reply
topstockalerts
topstockalerts Jul. 25 at 6:58 PM
$DYN she wants to move higher..
0 · Reply
Sam201
Sam201 Jul. 25 at 6:35 PM
$DYN told you to load!
0 · Reply
Latest News on DYN
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Jul 29, 2025, 12:51 PM EDT - 3 days ago

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 28, 2025, 4:10 PM EDT - 4 days ago

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

Jul 16, 2025, 7:00 AM EDT - 16 days ago

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jul 2, 2025, 4:01 PM EDT - 4 weeks ago

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Jul 1, 2025, 9:00 AM EDT - 4 weeks ago

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

PRGS TSLA

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Jun 30, 2025, 9:45 PM EDT - 4 weeks ago

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Jun 30, 2025, 4:05 PM EDT - 4 weeks ago

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

Jun 30, 2025, 4:01 PM EDT - 4 weeks ago

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

Jun 24, 2025, 3:43 AM EDT - 5 weeks ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Jun 18, 2025, 11:08 AM EDT - 6 weeks ago

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

Jun 17, 2025, 1:35 PM EDT - 6 weeks ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Jun 17, 2025, 7:00 AM EDT - 6 weeks ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Jun 16, 2025, 4:05 PM EDT - 6 weeks ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

Jun 5, 2025, 7:30 AM EDT - 2 months ago

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 7:30 AM EDT - 3 months ago

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Apr 24, 2025, 7:30 AM EDT - 3 months ago

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Apr 15, 2025, 7:30 AM EDT - 3 months ago

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 14, 2025, 4:30 PM EDT - 3 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Mar 20, 2025, 4:30 PM EDT - 4 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Mar 20, 2025, 4:10 PM EDT - 4 months ago

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Mar 16, 2025, 7:00 PM EDT - 4 months ago

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 13, 2025, 9:09 AM EDT - 5 months ago

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Mar 12, 2025, 3:05 PM EDT - 5 months ago

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Mar 11, 2025, 7:30 AM EDT - 5 months ago

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:30 AM EST - 5 months ago

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Feb 14, 2025, 4:05 PM EST - 6 months ago

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 7:30 AM EST - 6 months ago

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Jan 21, 2025, 7:30 AM EST - 6 months ago

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 1:40 PM EST - 7 months ago

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Jan 10, 2025, 6:30 AM EST - 7 months ago

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 7:30 AM EST - 7 months ago

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Jan 8, 2025, 4:05 PM EST - 7 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Nov 11, 2024, 6:15 PM EST - 9 months ago

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Dyne Therapeutics to Present at Upcoming Investor Conferences

Nov 7, 2024, 4:15 PM EST - 9 months ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 3, 2024, 11:00 AM EST - 9 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 9 months ago

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 9 months ago

Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 26, 2024, 11:00 AM EDT - 9 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 10 months ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions

Oct 17, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 16, 2024, 11:00 AM EDT - 10 months ago

Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Jewstock
Jewstock Aug. 1 at 4:34 PM
$DYN what’s happening here 😳
0 · Reply
JarvisFlow
JarvisFlow Jul. 31 at 3:51 PM
Stifel has adjusted their stance on Dyne Therapeutics ( $DYN ), setting the rating to Buy with a target price of 66 → 36.
0 · Reply
Sam201
Sam201 Jul. 30 at 5:31 PM
$DYN load whenever it dips!
0 · Reply
Jewstock
Jewstock Jul. 30 at 2:15 PM
$DYN let’s go!
0 · Reply
anachartanalyst
anachartanalyst Jul. 29 at 11:01 AM
$DYN https://anachart.com/wp-content/uploads/ana_temp/1753786884_soc-img.jpg
0 · Reply
DonCorleone77
DonCorleone77 Jul. 28 at 8:14 PM
$DYN Dyne Therapeutics reports Q2 EPS (97c), consensus (93c) -- Dyne Therapeutics expects cash to fund operations into Q3 of 2027
0 · Reply
Sam201
Sam201 Jul. 28 at 3:39 PM
$DYN got myself another 300 shares!
0 · Reply
StocksNCash
StocksNCash Jul. 25 at 7:13 PM
$DYN looking 💪
0 · Reply
topstockalerts
topstockalerts Jul. 25 at 6:58 PM
$DYN she wants to move higher..
0 · Reply
Sam201
Sam201 Jul. 25 at 6:35 PM
$DYN told you to load!
0 · Reply
theBigDollarski
theBigDollarski Jul. 25 at 6:34 PM
$DYN Sha-boink...what gives... $SRPT in the sh!tcan and $DYN is the faschizzle?
0 · Reply
Soorena
Soorena Jul. 25 at 6:28 PM
$DYN what’s the news?
0 · Reply
Jewstock
Jewstock Jul. 25 at 2:59 PM
$DYN come on man
0 · Reply
Jewstock
Jewstock Jul. 18 at 2:20 PM
$DYN took some profits to buy more $TTWO
0 · Reply
Jewstock
Jewstock Jul. 17 at 3:34 PM
$DYN back in the green here
0 · Reply
DougAfter60
DougAfter60 Jul. 17 at 3:00 PM
$DYN picked up a bit…so far so good…
0 · Reply
MGeronimo
MGeronimo Jul. 17 at 1:03 AM
$DYN IN AT 9.43 on insider buying
0 · Reply
Jewstock
Jewstock Jul. 16 at 7:43 PM
$DYN let’s go!
0 · Reply
G101SPM
G101SPM Jul. 16 at 2:13 PM
#INSIDERS $DYN CEO & President bought (and gfited) 100,000 shares at $9.02 - $9.15 worth about $911K. $HELE Chief Executive Officer and Chief Financial Officer bought 20,000 shares at $20.13 - $21.48 worth approximately $416K. $AMZN founder Jeffrey Bezos disclosed the sale of 6,715,424 shares pursuant to a Rule 10b5-1 trading plan worth more than $1.5 bln.
0 · Reply
Florestan
Florestan Jul. 16 at 1:27 PM
$MSCLF Satellos Bioscience Inc., developing a small molecule to restore asymmetric division in stem cells in vivo to treat Duchenne, announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer (“CMO”). Dr. Farwell joins Satellos from Dyne Therapeutics (Nasdaq: $DYN), where he most recently served as CMO and medical advisor. Satellos will be submitting IND-enabling package to global regulators this quarter to begin Phase 2 in an RCT setting to prove the hypothesis that the lack of dystrophin in muscle stem cell is causing impaired regeneration, thus explaining the progressively fatal nature of the disease. https://ir.satellos.com/news/news-details/2025/Satellos-Appoints-Dr--Wildon-Farwell-as-Chief-Medical-Officer/default.aspx
0 · Reply
Jewstock
Jewstock Jul. 16 at 1:29 AM
$DYN chat gpt is saying short interest is between 14-17%, possibility for a squeeze
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 15 at 11:15 PM
$DYN CEO purchased 100,000 shares at $9.11 for a total of $911,000. Cox John now owns 314,179 shares. https://ceo-buys.com
0 · Reply